Abstract:Objective: To compare the diagnostic efficacy of AI-guided mpMRI-TRUS fusion assisted transperineal systematic biopsy, targeted biopsy and combined biopsy in the diagnosis of PCa, and to evaluate the clinical application value of combined biopsy. Methods: From April 2022, the general personal information and clinical data of patients with suspicious prostate lesions (PI-RADS≥3) detected by 3.0T mpMRI were collected, then underwent AI-guided mpMRI-TRUS fusion-assisted transperineal prostate biopsy. The data included age, PSA level, PV, PSAD, PI-RADS score, Gleason score of biopsy tissue, etc. The mpMRI image data were imported into the real-time fusion imaging system before biopsy. After image fusion, the suspected PCa lesion was taken as the target, 2 to 3 cores of targeted biopsy were first performed, then 12 cores of systematic biopsy were continued. The results of targeted biopsy + systematic biopsy were defined as the results of combined biopsy. The detection rate of PCa, CsPCa and pathological Gleason score were compared among different biopsy methods, and the diagnostic efficacy in different PI-RADS score groups was further evaluated. Results: A total of 118 PCa cases were detected in 220 patients enrolled in this study. The PCa detection rates of systematic biopsy and targeted biopsy were 40.45% and 43.64%, the result reveals no statistical significance (P=0.562). The PCa detection rate of combined biopsy was 53.64%, higher than single biopsy method and the differences were statistically significant (P<0.05). The detection rates of CsPCa in systematic biopsy and targeted biopsy were 28.18% and 37.27% which reveals significant statistical difference (P=0.042). The CsPCa detection rate of combined biopsy was 41.82%, higher than single biopsy method, the difference was statistically significant compared with systematic biopsy (P=0.003), but was not compared with targeted biopsy (P=0.330). In PI-RADS score 3 group, the PCa detection rate of systematic biopsy and targeted biopsy was 39.29% and 21.43%, which reveals no statistical significance (P=0.146). The PCa detection rate of combined biopsy was 50%, higher than single biopsy method, the difference was statistically significant compared with targeted biopsy (P=0.026), but was not compared with systematic biopsy (P=0.420). In PI-RADS 4 ~5 group, the PCa detection rate of systematic biopsy and targeted biopsy was 40.10%, and 46.88% which reveals no statistical significance (P=0.181). The PCa detection rate of combined biopsy was 54.17%, higher than single biopsy method, the difference was statistically significant compared with systematic biopsy (P=0.006), but was not compared with targeted biopsy (P=0.153). Among PCa patients detected by both systematic and targeted biopsy, 39 had concordant pathologic Gleason scores, 13 had escalating pathologic Gleason scores for systematic biopsy, and 18 had escalating pathologic Gleason scores for targeted biopsy. Conclusion: Compared with systematic biopsy, AI-guided mpMRI-TRUS image fusion assisted transperineal targeted prostate biopsy has a higher detection rate of CsPCa and is probably closer to the true pathological Gleason score. Compared with single biopsy, combined biopsy has higher diagnostic efficiency for PCa, which can be used as one of the options of prostate biopsy in clinical practice.

Combination of serum PSA assay, multi-parametric MRI and targeted prostate biopsy for prostate cancer screening in Nanjing

MP13-07 COMBINATION OF SERUM PSA, MPMRI AND PROSTATE TARGETED BIOPSY FOR PROSTATE CANCER SCREENING IN NANJING

The value of combined detection of PCA3 mRNA and PSA mRNA in peripheral blood of patients with prostate cancer

Applied Research of Prostate Specific Antigen Combined with Prostate Cancer Gene 3 in Diagnosis of Prostate Disease

Diagnostic Performance of PCA3 and Hk2 in Combination with Serum PSA for Prostate Cancer.

Current status of prostate biopsy in Chinese Prostate Cancer Consortium member hospitals

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

Combination Of Ga-68-Psma Pet/Ct And Multiparametric Mri Improves The Detection Of Clinically Significant Prostate Cancer: A Lesion-By-Lesion Analysis

Does PSA level affect the choice of prostate puncture methods among MRI-ultrasound fusion targeted biopsy, transrectal ultrasound systematic biopsy or the combination of both?

Percent Free Prostate-Specific Antigen for Prostate Cancer Diagnosis in Chinese Men with a PSA of 4.0–10.0 Ng/ml: Results from the Chinese Prostate Cancer Consortium

Can the Combination of Biparametric Magnetic Resonance Imaging and PSA‐related Indicators Predict the Prostate Biopsy Outcome?

The prostate cancer precision screening program:a preliminary report after recruitment of 2159 men

The value of prostate specific antigen density in the detection of prostate cancer by the multi-parametric MRI

Combination of 68Ga-Psma PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis.

Mass Screening of 12,027 Elderly Men for Prostate Carcinoma by Measuring Serum Prostate Specific Antigen.

[Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy]

Combining Clinical Parameters and Multiparametric Magnetic Resonance Imaging to Stratify Biopsy-Naïve Men for an Optimum Diagnostic Strategy with Prostate-Specific Antigen 4 Ng Ml−1 to 10 Ng Ml−1

MP13-20 COMBINATION OF 68GA-PSMA PET/CT AND MULTIPARAMETER MRI IMPROVES THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A LESION BY LESION ANALYSIS

Combined MRI-TRUS fusion targeted and systematic biopsy versus systematic biopsy alone for the detection of prostate cancer: protocol for a prospective single-centre trial

Dual‐Enhanced SERS Satellite Immuno‐Nanocomplex for Multiple PSA‐Mediated PHI Assay Toward Clinical Prostate Cancer Screening

[The Prostate Cancer Precision Screening Program: a Preliminary Report after Recruitment of 2 159 Men].